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INTRODUCTION 
Stroke is a non-communicable disease among the elderly 
population that is the third leading cause of death in 
developed countries after coronary artery diseases and 
cancers. According WHO report, 56.4 million deaths 
occurred worldwide in 2015 that 54% of them were among 
the top ten causes of death. Yearly about 750000 stroke 
have been occurred in USA and about 150000 of them 
have been died due to stroke. The incidence of stroke 
increases with age and about two third of stroke cases 
occur in upper 65 years old. In Iran the occurrence of 
stroke 10 year lower than world and several risk factors 
including age, sex, alcohol, smoking, high cholesterol, 
OCP, genetic and HTN are involved in the pathogenesis of 
stroke among people. Stroke is the main cause of physical 
disability among society’s people which ws characterized 
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by the onset of acute neurological symptoms for 24 
hours.1-4 
Neurological symptoms are caused by the involvement of 
the central nervous system as a result of impaired cerebral 
blood flow which was determined by getting history. The 
location of the CNS is guessed according to the type of 
symptoms and diagnosed by neurologic examination and 
confirmed by uses CT-scan and MRI.2,3,5,6 
The UKPDS study reported that treatment with Metformin 
decreases the risk of large vascular disease similar to small 
vascular disease. This is the opposite of other therapies that 
only reduce the deaths caused by sall vessels. The study 
showed that metformin protects cells from hypoxia and 
non-neuronal ischemia.  
The protective effects of metformin may be due to AMPK 
activity. Research results indicated that metformin 
injection was performed 30 minutes after reperfusion 
injury in a complete brain ischemia in animal models 
involving 4 brain vessels and the deaths of the cells 
advance toward apoptosis.7-9 
Also cerebrovascular disease is the most common 
neurological disease which can lead to complications or 
mortality. The incidence of ischemic stroke increases with 
age, and almost two thirds of cases occur in people over 65 
years.10 
Considering the protective effects of metformin in 
preventing secondary damage and due to lack of similar 
study in this area, the aim of this study was to investigate 
the impact of Metformin on the Severity and Outcomes of 
Ischemic Stroke. 
METHODS 
Study design and patients  
This clinical trial study has been done on 100 patients with 
ischemia stroke which randomly assigned to two groups A 
and B. Inclusion criteria of the study is Ischemic stroke 
patients and focal neurological symptoms. Exclusion 
criteria of the study is intracerebral hemorrhage (ICH); 
Subarachnoid hemorrhage (SAH); subdural hematoma 
(SDH); hypoglycemia; contraindications for metformin 
use; diabetic patients; venous sinus thrombosis and drug 
side effects. The National Institutes of Health Stroke Scale 
(NIHSS) will be used to evaluate the clinical 
manifestations of ischemic stroke. Two groups were 
followed-up for three month and Metformin 500 mg was 
administrated for patients in group A and placebo for 
patients in group B twice a day for seven days. If any 
complications are detected, the patient will be excluded 
from the study. 
Blood glucose in patients each 6 hour was checked and 
registered in chart of BS and in case of see any 
complications, the patient extracted from the study. Before 
start the intervention, the NIHSS questionnaire was 
completed in baseline and 1, 3, 7 days and 1, 2 and 3 month 
after intervention completed for follow-up.  
NIHSS questionnaire  
The questionnaire NIHSS formed of 11 questions and the 
total score is in range 0 to 42 and each question had score 
0 to 4. The score 0 for normal performance and the high 
scores show the upper degree of neourologic disorders in 
patients. The necessary tests such as level of consciousness 
(LOC), Eye movements, Field of vision, Fractional 
paresis, Arm movements (paralysis), Foot movements, 
Ataxia and sensory impairment, Ability to speak and 
Dysarthria was performed according to standard criteria of 
patients.  
Statistical methods 
Collected data were analyzed by statistical methods in 
SPSS version 19.  
RESULTS 
There were Fifty sex present of all patients were male and 
rest of them were female. The mean age of patients in 
Metformin group (A) was 68.9±10.6 years (range 42-90) 
and placebo group (B) was 67±11.63 years (range 41-86). 
The prevalent stroke risk factor was HTN with 43%. 
Cortical stroke  
The difference in NIHSS scores between two groups in 
patients with cortical stroke wasn’t significant in days 1 
(p=0.5), 2 (p=0.66) and 7 (p=0.18) after treatment by 
Metformin but the difference was significant in end of first 
month (p=0.038), second month (p=0.001) and third 
month (p=0.001) (Figure 1). 
 
Figure 1: Compare the mean of NIHSS scores 
between two groups by times after intervention in 
cortical stroke. 
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Brain stem stroke 
The difference in NIHSS scores between two groups in 
patients with brain stem stroke wasn’t significant in days 
1 (p=0.75), 2 (p=0.56) and 7 (p=0.48) after treatment by 
Metformin and in the end of first month (p=0.57), second 
month (p=0.51) and third month (p=0.33) (Figure 2). 
 
Figure 2: Compare the mean of NIHSS scores 
between two groups by times after intervention in 
brain stem stroke. 
Lacunar stroke  
The difference in NIHSS scores between two groups in 
patients with Lacunar stroke wasn’t significant in days 1 
(p=0.69), 2 (p=0.58) and 7 (p=0.51) after treatment by 
Metformin and in the end of first month (p=0.46), second 
month (p=0.55) and third month (p=0.21) (Figure 3). 
 
Figure 3: Compare the mean of NIHSS scores 
between two groups by times after intervention in 
lacunar stroke. 
DISCUSSION 
In line with our study, Mima and et al in a study in 2016, 
showed that treatment with Metformin in patients with 
stroke was associated with mild brain symptoms 
(p=0.026). But neural function didn’t show significant 
relation. Also patients with history of stroke, gain taking 
Metformin on improving symptoms (p=0.046).5 
According to the Wu and et al study in 2016 which has 
been done on ICH diabetic patients, results showed that 
Metformin was related with death below 90 days 
(p=0.014) which was in line with our study results.11 
Venna and et al in study 2014, showed that there was 
inconsistent evidence on effect of metformin on RSN as a 
marker for mortality in repeated CV and Atrothrombotic 
ischemia stroke.12 
According to the study of Kuwashiro and et al in 2012, 
using metformin in patients with stroke to prevent, had 
about 9% positive and 6% negative results that there 
wasn’t significant relation between taking metformin and 
occurrence stroke. The severity of stroke defined by 
NIHSS and the mild neurologic defined as a score low than 
3 for NIHSS. According to the function results, 
postoperative dysfunction after discharge assesed by MRS 
and the desirable performance defined as MRS score 2 or 
below.7,13 
There was significant difference between patients which 
used metformin before stroke and in diabetic patints that 
not had proper treatment. On the other hand, given the 
effects of the previous use of anti-diabetic drugs, currently 
there was no evidence indicating the improvement in the 
severity or outcome of stroke.8,9,12-15 
In contrast, use metformin was considered as a proper 
factor in reducing the severity of stroke in the study 
population of Mima and et al, study that in non-diabetic 
patients with stroke (64% of all patients), about 75% had 
NIHSS below 3 and the effects of metformin was observed 
on functional outcomes only in the mild to severe stroke. 
In addition to the initial score of NIHSS, occurrence of 
stroke relapse was related with increasing stroke severity 
and mild prognosis of stroke.5,16,17 
Jiang and et al in a study showed that the drugs such as 
metformin, pioglitazone and semaglutin were effective in 
the decreasing the risk of stroke.18 
In a sample of 14856 diabetic patients from Taiwan after 4 
years follow-up, the relation between metformin uses and 
stroke reducing wasn’t significant. A multi-center study 
conducted in 1998 by UKPDS, presented evidence that 
treatment with metformin in comparison with insolin and 
SU deal to reducing the coronery side effects related to the 
T2D that’s it deals to accelerate the use of metformin in 
diabetic treatment.13,19 
In this study in line with other studies, results showed that 
taking metformin in non-diabetic patients with stroke 
could cause to decreasing the stroke intensity and its 
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effects such as functional effects which was assessed in 
this study by NIHSS. 
CONCLUSION 
In cortical stroke, the difference in NIHSS between two 
groups wasn’t significant in first, third and seventh day 
after intervention but it was significant in one, two and 
three months after intervention. The results of this study 
showed that taking metformin was reduced the intensity 
and symptoms of stroke and also deal to accelerated 
recovery and functional output in patients with cortical 
stroke one, two and three months after intervention. 
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